A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

To join this study, you need to be at least 18 years old. You must have been diagnosed with a specific type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to other parts of your body. It's also important that you haven't had any previous drug treatment for this type of advanced lung cancer.

There are also some reasons why you might not be able to join. For example, if you can't or won't take certain vitamins (folic acid and vitamin B12) or if you've had a very severe allergic reaction to similar treatments or any part of the study drugs (SB27, Keytruda, or the chemotherapy).

The research team will carry out several tests to make sure the study is suitable and safe for you. Women who can become pregnant will need to agree to use reliable birth control during the study.

If you decide to take part in this study, you would receive either the investigational drug SB27 or the approved drug Keytruda, alongside standard chemotherapy. Both of these treatments would be given to you every three weeks. During your time in the study, you would have regular visits to the clinic for your treatments, as well as to check your health and how you are responding to the medication. This would involve regular physical exams, blood tests, and scans. The exact total duration of your participation would be explained by the study team, but typically, you would continue treatment as long as it benefits you and is safe, followed by a period of follow-up check-ups.